Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...

Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise The single-dose pen does not require mixing nor ...

Another glucagon-like peptide-1 (GLP1) agonist, dulaglutide (Trulicity, Lilly), is poised to be a new option for glycemic control in youth ages 10 to 18 with type 2 diabetes, given as a weekly ...

Trulicity Pen Now Available for Type 2 Diabetes Eli Lilly announced the launch of Trulicity (dulaglutide) pen indicated as adjunct to diet and exercise to ipmrove glycemic control in adults with type ...

Eli Lilly announced results from a head-to-head study comparing dulaglutide (Trulicity) to insulin glargine (Lantus; Sanofi Aventis) for hemoglobin A1c (HbA1C) reduction in patients with type 2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA approved two additional doses of the once-weekly ...